Jefferies Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
TD Cowen: 'We view yesterday's announcement as highly positive for PRAX'
December 31, 2025 7:16 AM ESTTD Cowen analyst Ritu Baral reiterated a Buy rating and $353.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Yesterday AM, PRAX announced it was granted Breakthrough Designation (BTD) for ulixa in Essential Tremor (ET). As a reminder, per the FDA website, BTD is a process designed to expedite the development and review of drugs... More



